158 related articles for article (PubMed ID: 6432305)
1. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
Klein HO; Wickramanayake PD; Christian E; Coerper C
Cancer; 1984 Sep; 54(6 Suppl):1193-203. PubMed ID: 6432305
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of single-push or fractionated injections of cyclophosphamide or ifosfamide combined with mesna.
Klein HO; Wickramanayake PD; Christian E; Coerper C; Graf L
Cancer Treat Rev; 1983 Sep; 10 Suppl A():83-92. PubMed ID: 6414699
[No Abstract] [Full Text] [Related]
3. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Loeffler TM; Weber FW; Hausamen TU
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
[TBL] [Abstract][Full Text] [Related]
4. High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
Klein HO; Wickramanayake PD; Coerper C; Christian E; Pohl J; Brock N
Cancer Treat Rev; 1983 Sep; 10 Suppl A():167-73. PubMed ID: 6414691
[No Abstract] [Full Text] [Related]
5. Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
Cerny T; Graf A; Rohner P; Zeugin T; Brunner KW; Küpfer A
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S129-34. PubMed ID: 1795001
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
Scheulen ME; Niederle N; Bremer K; Schütte J; Seeber S
Cancer Treat Rev; 1983 Sep; 10 Suppl A():93-101. PubMed ID: 6414700
[TBL] [Abstract][Full Text] [Related]
7. Infusion of ifosfamide plus mesna.
Rowland CG; Bradford E; Adams P; Haines-Nutt RP; Jakobson K
Lancet; 1984 Aug; 2(8400):468. PubMed ID: 6147537
[No Abstract] [Full Text] [Related]
8. Infusion of ifosphamide plus mesna.
Shaw IC; Rose JW
Lancet; 1984 Jun; 1(8390):1353-4. PubMed ID: 6145051
[No Abstract] [Full Text] [Related]
9. Dosing and side-effects of ifosfamide plus mesna.
Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.
Stuart-Harris R; Harper PG; Kaye SB; Wiltshaw E
Cancer Treat Rev; 1983 Sep; 10 Suppl A():163-4. PubMed ID: 6414689
[No Abstract] [Full Text] [Related]
11. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
Brock N; Pohl J; Stekar J
J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
Skubitz KM; Hamdan H; Thompson RC
Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide in experimental tumor systems.
Goldin A
Semin Oncol; 1982 Dec; 9(4 Suppl 1):14-23. PubMed ID: 6761864
[No Abstract] [Full Text] [Related]
14. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Dechant KL; Brogden RN; Pilkington T; Faulds D
Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
[TBL] [Abstract][Full Text] [Related]
15. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
[TBL] [Abstract][Full Text] [Related]
16. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
[TBL] [Abstract][Full Text] [Related]
17. Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
Hilgard P; Burkert H
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1451-2. PubMed ID: 6437825
[No Abstract] [Full Text] [Related]
18. Ifosfamide--current aspects and perspectives.
Hilgard P; Herdrich K; Brade W
Cancer Treat Rev; 1983 Sep; 10 Suppl A():183-92. PubMed ID: 6414693
[No Abstract] [Full Text] [Related]
19. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
Mohrmann M; Ansorge S; Schönfeld B; Brandis M
Pediatr Nephrol; 1994 Aug; 8(4):458-65. PubMed ID: 7524598
[TBL] [Abstract][Full Text] [Related]
20. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
